🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I am excited to share our new work on personalized mRNA vaccines in pancreatic cancer in nature: nature.com/articles/s4158… Great thread below by Vinod BalachandranMD explaining the findings. As always, it is a pleasure to be part of this team with such great colleagues and friends.

Hot off the press in nature! 🔥 Lead authors Zachary Sethna and Pablo Guasp and their colleagues show that autogene cevumeran can generate strong and durable CD8+ T cell immunity in #PDAC that correlates with delayed recurrence. Congratulations to the team! 👏

Nature research paper: RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer go.nature.com/3X76JvB

The same for a personalized neaontigen vaccine vs pancreatic cancer nature.com/articles/s4158… nature

First, good news in the fight against #pancreaticcancer! ASPIRE awardee Ben Greenbaum (Benjamin D. Greenbaum) of Memorial Sloan Kettering Cancer Center found that an mRNA neoantigen vaccine induces long-lived CD8+ T cells (potentially lasting decades!), which may delay recurrence. nature.com/articles/s4158…

2-4pm est on local public radio - fun chat on cancer vaccines w Science Friday Flora Lichtman 👇🏾 sciencefriday.com/segments/pancr… 🧵 👉🏾 x.com/TheVinodLab/st…

Great to chat with Science Friday and Flora Lichtman! Link to audio below.

A new paper shows that personalized pancreatic cancer vaccines can keep patients cancer-free for YEARS - an incredible outcome for a cancer with only a 7% 5-year survival rate.

We are incredibly grateful for the support of The Marcus Foundation. This generous grant marks the beginning of an exciting new partnership to discover and advance next-generation cancer vaccines – we are excited about the possibilities ahead!

I had a fun time chatting with Derek Thompson about cancer vaccines. Check it out.

Pancreatic cancer — a disease with a 90% mortality rate — has long been a grim diagnosis. But that may be changing. Meet Vinod Balachandran, the lead researcher behind a groundbreaking mRNA vaccine that’s transforming the outlook for patients. Credits : Richard Hanania

I am moved by the passion and expertise of the remarkable team at the Olayan Center for Cancer Vaccines (Olayan CCV) and was excited to celebrate their continued work at the Olayan CCV Open House. The standing room-only event brought together Memorial Sloan Kettering Cancer Center cancer vaccine

A new mRNA vaccine could prevent pancreatic cancer from returning — potentially for the long haul. sciencenews.org/article/cancer…

MSK researchers are trying to understand how the immune system senses cancer in order to make better #immunotherapies. "If we can figure out generally what the immune system is sensing — and how it affects how cancers grow, spread, and adapt," says Benjamin D. Greenbaum, a computational

Grateful & humbled to make the 2025 #TIME100HEALTH list with such inspiring global health leaders. This honor reflects my team, who are unrelenting in their efforts to advance new treatments for pancreatic cancer!

💡 Vinod Balachandran, Director of the Olayan Center for Cancer Vaccines at Memorial Sloan Kettering Cancer Center, will explain how mRNA vaccine technology is transforming cancer treatment.

Congratulations Chrysothemis Brown! Fantastic!!

Excited to share our study describing a role for a subset of Thetis cells, TC IV, in tolerance to food antigens. A team effort led by Vanja Cabric and Yollanda Parisotto 🧵 1/ science.org/doi/10.1126/sc…